SlideShare une entreprise Scribd logo
1  sur  20
Télécharger pour lire hors ligne
Advanced Cell Technology
Corporate Presentation
March 2010
1
This presentation is intended to present a summary of ACT’s (“ACT”, or “Advanced
Cell Technology Inc”, or “the Company”) salient business characteristics.
The information herein contains “forward-looking statements” as defined under the
federal securities laws. Actual results could vary materially. Factors that could cause
actual results to vary materially are described in our filings with the Securities and
Exchange Commission.
You should pay particular attention to the “risk factors” contained in documents we
file from time to time with the Securities and Exchange Commission. The risks
identified therein, as well as others not identified by the Company, could cause the
Company’s actual results to differ materially from those expressed in any forward-
looking statements.
Cautionary Statement Concerning Forward-Looking
Statements
2
ACT Therapeutics
ACT Proprietary Human
Therapeutic Programs
Treatment Clinical Stage
Blastomere Program
Development of embryonic stem cell lines without
destruction of embryo
Pre-Clinical
Retinal Pigment Epithelium
(RPE) Program
Treatment of Age-related Macular Degeneration
(AMD) and Retinal Degenerative Diseases
Clinical IND
awaiting
FDA approval
Myoblast Program
Treatment of Heart Disease, Heart Attack and
Heart Failure
Phase II
Hemangioblast program
Treatment of Diseases and Disorders of the
Circulatory and Vascular Systems
Pre-Clinical
3
Pending
Multiple next generation technologies complementary to
existing patents and claims
PendingMultiple use patents for heart disease
StatusUse Patents
PendingCombinations of myoblasts and stem cells
PendingCombinations of myoblasts and muscle survival factors
PendingCatheter delivery of cells
AwardedMedia for preservation and transplant of muscle cells
AwardedStem cells capable of forming nerve or muscle cells
AwardedMuscle cells
StatusComposition of Matter Patent
Intellectual Property Protection
ACT owns or licenses over 150 patents and patent applications related to
stem cell and regenerative therapies
4
Institutional Collaborators
Advanced Cell’s Institutional Collaborators include:
Casey Eye Institute Mayo Clinic
Moran Eye Institute UCSF
Harvard Johns Hopkins
Stanford Sloan Kettering
University of Florida University of Iowa
University of Illinois U.C. Berkeley
Colorado State University
5
Blastomere Program: Synthesizing Stem Cells
without Harm to the Embryo
•Company scientists successfully generate stem
cell lines without destruction of embryo
•Cell lines retain potential to form all cells in the
human body
•Potential to treat a range of human diseases
•Technology has been reproduced and peer-
reviewed on several occasions
•National Institute of Health (NIH) proposing
expanded funding regulations to accommodate
ACT’s lines
6
First Proven Alternative hESC Method
•Enables Derivation of New hESC Lines
via Pre-implantation Genetic Diagnosis
(PGD) Method, Preserving Development
Potential of the Embryo
•7 hESC lines awaiting NIH approval for
funding
•Technology is used to develop RPE cells for
our clinical trials for Stargardt’s disease
Hemangioblasts
Differentiated from
Blastomere hESC Lines
7
RPE Program: Why RPE?
• Pigmented epithelium cells are easy to identify
• Small dosage vs. other therapies
• The eye is an immune-privileged site, thus no risk
of rejection at the injection site
• Ease of administration
– Doesn’t require a separate approval by the FDA (universal applicator)
– Procedure is already used by eye surgeons; no new skill set required
for doctors
• RPE cell therapy may positively impact over 200 retinal diseases
8
RPE Program Status
Complete Stage 1 of Phase I Clinical Trial for
Stargardt’s disease2010 – 4th Quarter
Developed the “Proof of Concept” for ACT’s RPE
cells in RCS animal model2006
Pre – IND meeting with FDA2008
Filed IND for Stargardt’s disease2009
FDA approval2010 – 3rd Quarter
9
GMP-compliant Human RPE Cells Derived from Embryonic Stem Cell
Lines Rescue Visual Function In a Rat Model for Photoreceptor
Degeneration
“Our results show that a well-characterized GMP-compliant embryonic stem cell-derived RPE
cells can survive after transplantation to the sub-retinal space of RCS rats, integrate into host
RPE layer without migration into the retina and continue to express at least some of the
molecules characteristic of RPE. The cells are effective in rescuing photoreceptors from
degeneration and result in significant rescue of visual function over sham-operated animals for
the long term.”
CASEY EYE
INSTITUTE
10
Myoblast Program Highlights
Target Market for Myoblast Program
Sufferers of Heart Failure, Chronic Heart
Failure and patients with scarred or
ischemic (dead) heart tissue caused by
or related to heart attack
Program Status
Clearance from FDA to Proceed with
Phase II Clinical Trials in the U.S.
Charlestown, MA GMP Facility
11
Myoblast Program: Clinical Trial Summary
Phase 1
LVAD
Phase 1
CABG
Phase 1b
CABG
Phase 1b
Catheter
Patients 6 patients 12 patients 12 patients
23 Patients
(12 treated,
11 control)
Indication
LVAD Bridge
to Transplant
+CABG +CABG Catheter Injection
Dose
Single Dose -
300 MM Cells
Escalating –
10, 30, 100 and
300 MM Cells
Single Dose -
300 MM Cells
Escalating -
30, 100, 300 and
600 MM Cells
Primary
Endpoint
Safety Safety Safety Safety
Result
Demonstrated
cell survival in
humans
Dose
escalation, Safe
at all doses
Survival of cells
(cardiac
imaging),
improved
symptoms and
function
Safe at all doses,
improved
symptoms and
function
12
Myoblast Program: Phase II Clinical Trial
 80 total patients (1:1 treatment vs. control)
 Double-blind, placebo-controlled (sham procedure)
 Catheter delivery of cells: percutaneous targeted delivery
 Three-month, six-month, and 12-month follow-up
 Endpoints: Improvement in HF symptoms and Ventricular
Volumes
 Primary endpoint: Improvement in heart failure symptoms
measured by “Kansas City Cardiomyopathy Questionnaire”
 Supporting endpoints: Ventricular volumes, Six minute walk test
 Interim data analysis at six-months by Independent Review Board
13
Hemangioblast Program: Partnership
• Joint Venture with leading Korean stem cell
developer CHA Biotech Co.
• The J.V., ‘Stem Cell & Regenerative
Medicine International’, is focused on the
development of human blood cells and
related products
14
Hemangioblast Program: Overview
The HG cell is the precursor to all cell types in the
circulatory and vascular systems
15
Hemangioblast Program: Synthesizing Blood Cells
16
The ACT Therapeutic Timeline
Timetable for Therapeutic Program Milestones Period
Received Orphan indication from Department of Health
and Human Services
Q1 2010
Completion of end of life tumorgenicity & biodistribution
Q1 2010
Receive FDA clearance to commence with Phase I Clinical
Trials
Q3 2010
Treat 1st Patient in history with a hECS-based therapy Q3 2010
1st Quadrant Safety Data on Treated Patients Q4 2010
File 2nd Phase I IND for another Retinal Disease
2nd half
2010
Announce 2nd cellular-based IND in area other than
retinal program
2nd half
2010
studies for RPE
17
The Advanced Cell Technology Team
World Class Scientific Team lead by
Seasoned Management Team:
Dr. Robert Lanza, M.D. – Chief Scientific Officer
Dr. Jonathan Dinsmore, PhD – Myoblast Project Advisor
Edmund Mickunas – Vice President of Regulatory
William Caldwell IV – Chief Executive Officer
Rita Parker – Director of Operations
Roger Gay, PhD – Senior Director of Manufacturing
Matthew Vincent, PhD – IP / Licensing Advisor
18
State of the Company
• Two years of cash available
• Phase I/II trial fully funded
• Anticipating cell lines will qualify for
federal funding
• Actively pursuing development partners
offshore to accelerate development of
programs
19
Thank you for your time
For more information, visit www.advancedcell.com
Advanced Cell Technology is traded on the OTC BB, symbol: ACTC

Contenu connexe

Tendances

Presentation at BioPartnering Europe Conference, London. October 2010
Presentation at BioPartnering Europe Conference, London. October 2010Presentation at BioPartnering Europe Conference, London. October 2010
Presentation at BioPartnering Europe Conference, London. October 2010Advanced Cell Technology, Inc.
 
Presentation at Stem Cell Meeting on the Mesa, La Jolla, Calif., November 30,...
Presentation at Stem Cell Meeting on the Mesa, La Jolla, Calif., November 30,...Presentation at Stem Cell Meeting on the Mesa, La Jolla, Calif., November 30,...
Presentation at Stem Cell Meeting on the Mesa, La Jolla, Calif., November 30,...Advanced Cell Technology, Inc.
 
2013 Aegis Capital Healthcare Conference, Sept 26th 2013
2013 Aegis Capital Healthcare Conference, Sept 26th 20132013 Aegis Capital Healthcare Conference, Sept 26th 2013
2013 Aegis Capital Healthcare Conference, Sept 26th 2013Advanced Cell Technology, Inc.
 
Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...
Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...
Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...Advanced Cell Technology, Inc.
 
Presentation at the Rodman & Renshaw Global Investment Conference, NYC, Sept....
Presentation at the Rodman & Renshaw Global Investment Conference, NYC, Sept....Presentation at the Rodman & Renshaw Global Investment Conference, NYC, Sept....
Presentation at the Rodman & Renshaw Global Investment Conference, NYC, Sept....Advanced Cell Technology, Inc.
 
ARM's Regen Med Investor Day, New York City, April 17, 2013
ARM's Regen Med Investor Day, New York City, April 17, 2013ARM's Regen Med Investor Day, New York City, April 17, 2013
ARM's Regen Med Investor Day, New York City, April 17, 2013Advanced Cell Technology, Inc.
 
Act corporate presentation bioceo - february 2014- print version
Act corporate presentation   bioceo - february 2014- print versionAct corporate presentation   bioceo - february 2014- print version
Act corporate presentation bioceo - february 2014- print versionJohn Redaelli
 
Clinical Outlooks for Regenerative Medicine, Boston. June 2012
Clinical Outlooks for Regenerative Medicine, Boston. June 2012Clinical Outlooks for Regenerative Medicine, Boston. June 2012
Clinical Outlooks for Regenerative Medicine, Boston. June 2012Advanced Cell Technology, Inc.
 
Ocata corp-presentation-september-2015-2-4
Ocata corp-presentation-september-2015-2-4Ocata corp-presentation-september-2015-2-4
Ocata corp-presentation-september-2015-2-4John Redaelli
 
Act corporate presentation may 2014 - print version
Act corporate presentation   may 2014 - print versionAct corporate presentation   may 2014 - print version
Act corporate presentation may 2014 - print versionJohn Redaelli
 
Act corporate-presentation---may-2013---wscrm---print-version
Act corporate-presentation---may-2013---wscrm---print-versionAct corporate-presentation---may-2013---wscrm---print-version
Act corporate-presentation---may-2013---wscrm---print-versionJohn Redaelli
 

Tendances (16)

Presentation at BioPartnering Europe Conference, London. October 2010
Presentation at BioPartnering Europe Conference, London. October 2010Presentation at BioPartnering Europe Conference, London. October 2010
Presentation at BioPartnering Europe Conference, London. October 2010
 
Presentation at Stem Cell Meeting on the Mesa, La Jolla, Calif., November 30,...
Presentation at Stem Cell Meeting on the Mesa, La Jolla, Calif., November 30,...Presentation at Stem Cell Meeting on the Mesa, La Jolla, Calif., November 30,...
Presentation at Stem Cell Meeting on the Mesa, La Jolla, Calif., November 30,...
 
2013 Aegis Capital Healthcare Conference, Sept 26th 2013
2013 Aegis Capital Healthcare Conference, Sept 26th 20132013 Aegis Capital Healthcare Conference, Sept 26th 2013
2013 Aegis Capital Healthcare Conference, Sept 26th 2013
 
Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...
Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...
Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...
 
Presentation at the Rodman & Renshaw Global Investment Conference, NYC, Sept....
Presentation at the Rodman & Renshaw Global Investment Conference, NYC, Sept....Presentation at the Rodman & Renshaw Global Investment Conference, NYC, Sept....
Presentation at the Rodman & Renshaw Global Investment Conference, NYC, Sept....
 
ARM's Regen Med Investor Day, New York City, April 17, 2013
ARM's Regen Med Investor Day, New York City, April 17, 2013ARM's Regen Med Investor Day, New York City, April 17, 2013
ARM's Regen Med Investor Day, New York City, April 17, 2013
 
Stem Cell Meeting on the Mesa, Oct. 29, 2012
Stem Cell Meeting on the Mesa, Oct. 29, 2012Stem Cell Meeting on the Mesa, Oct. 29, 2012
Stem Cell Meeting on the Mesa, Oct. 29, 2012
 
Action proposal
Action proposalAction proposal
Action proposal
 
NYSSA Conference Presentation: B. Caldwell
NYSSA Conference Presentation: B. CaldwellNYSSA Conference Presentation: B. Caldwell
NYSSA Conference Presentation: B. Caldwell
 
Act corporate presentation bioceo - february 2014- print version
Act corporate presentation   bioceo - february 2014- print versionAct corporate presentation   bioceo - february 2014- print version
Act corporate presentation bioceo - february 2014- print version
 
Clinical Outlooks for Regenerative Medicine, Boston. June 2012
Clinical Outlooks for Regenerative Medicine, Boston. June 2012Clinical Outlooks for Regenerative Medicine, Boston. June 2012
Clinical Outlooks for Regenerative Medicine, Boston. June 2012
 
StayEstimate
StayEstimateStayEstimate
StayEstimate
 
Ocata corp-presentation-september-2015-2-4
Ocata corp-presentation-september-2015-2-4Ocata corp-presentation-september-2015-2-4
Ocata corp-presentation-september-2015-2-4
 
Act corporate presentation may 2014 - print version
Act corporate presentation   may 2014 - print versionAct corporate presentation   may 2014 - print version
Act corporate presentation may 2014 - print version
 
Act corporate-presentation---may-2013---wscrm---print-version
Act corporate-presentation---may-2013---wscrm---print-versionAct corporate-presentation---may-2013---wscrm---print-version
Act corporate-presentation---may-2013---wscrm---print-version
 
Boston sci
Boston sciBoston sci
Boston sci
 

En vedette

Top 9 embedded interview questions answers
Top 9 embedded interview questions answersTop 9 embedded interview questions answers
Top 9 embedded interview questions answersinterviews-job
 
8-й Seopub: "Email маркетинг сегодня: как продавать с помощью рассылок, чтобы...
8-й Seopub: "Email маркетинг сегодня: как продавать с помощью рассылок, чтобы...8-й Seopub: "Email маркетинг сегодня: как продавать с помощью рассылок, чтобы...
8-й Seopub: "Email маркетинг сегодня: как продавать с помощью рассылок, чтобы...Яна Сергиенко
 
Top 9 human resources interview questions answers
Top 9 human resources interview questions answersTop 9 human resources interview questions answers
Top 9 human resources interview questions answersinterviews-job
 
Microsoft Office PowerPoint 2007 - Lesson 2
Microsoft Office PowerPoint 2007 - Lesson 2Microsoft Office PowerPoint 2007 - Lesson 2
Microsoft Office PowerPoint 2007 - Lesson 2Samantha TerBeest
 
Top 9 jsf interview questions answers
Top 9 jsf interview questions answersTop 9 jsf interview questions answers
Top 9 jsf interview questions answersinterviews-job
 
Top 9 law enforcement interview questions answers
Top 9 law enforcement interview questions answersTop 9 law enforcement interview questions answers
Top 9 law enforcement interview questions answersinterviews-job
 
Top 9 education interview questions answers
Top 9 education interview questions answersTop 9 education interview questions answers
Top 9 education interview questions answersinterviews-job
 
Lindmoor Woods Neighborhood Watch Statistics from 10JULY11 to 31JULY13
Lindmoor Woods Neighborhood Watch Statistics from 10JULY11 to 31JULY13Lindmoor Woods Neighborhood Watch Statistics from 10JULY11 to 31JULY13
Lindmoor Woods Neighborhood Watch Statistics from 10JULY11 to 31JULY13Charles Maxwell MBA MHA PMP
 
Top 9 finance interview questions answers
Top 9 finance interview questions answersTop 9 finance interview questions answers
Top 9 finance interview questions answersinterviews-job
 
Top 9 drupal interview questions answers
Top 9 drupal interview questions answersTop 9 drupal interview questions answers
Top 9 drupal interview questions answersinterviews-job
 
Top 9 j2ee interview questions answers
Top 9 j2ee interview questions answersTop 9 j2ee interview questions answers
Top 9 j2ee interview questions answersinterviews-job
 
Top 9 jsp servlet interview questions answers
Top 9 jsp servlet interview questions answersTop 9 jsp servlet interview questions answers
Top 9 jsp servlet interview questions answersinterviews-job
 
Cisco Big Data Warehouse Expansion Featuring MapR Distribution
Cisco Big Data Warehouse Expansion Featuring MapR DistributionCisco Big Data Warehouse Expansion Featuring MapR Distribution
Cisco Big Data Warehouse Expansion Featuring MapR DistributionAppfluent Technology
 

En vedette (18)

Top 9 embedded interview questions answers
Top 9 embedded interview questions answersTop 9 embedded interview questions answers
Top 9 embedded interview questions answers
 
8-й Seopub: "Email маркетинг сегодня: как продавать с помощью рассылок, чтобы...
8-й Seopub: "Email маркетинг сегодня: как продавать с помощью рассылок, чтобы...8-й Seopub: "Email маркетинг сегодня: как продавать с помощью рассылок, чтобы...
8-й Seopub: "Email маркетинг сегодня: как продавать с помощью рассылок, чтобы...
 
Seoforum ирина бахмут
Seoforum ирина бахмутSeoforum ирина бахмут
Seoforum ирина бахмут
 
Top 9 human resources interview questions answers
Top 9 human resources interview questions answersTop 9 human resources interview questions answers
Top 9 human resources interview questions answers
 
Microsoft Office PowerPoint 2007 - Lesson 2
Microsoft Office PowerPoint 2007 - Lesson 2Microsoft Office PowerPoint 2007 - Lesson 2
Microsoft Office PowerPoint 2007 - Lesson 2
 
Top 9 jsf interview questions answers
Top 9 jsf interview questions answersTop 9 jsf interview questions answers
Top 9 jsf interview questions answers
 
Top 9 law enforcement interview questions answers
Top 9 law enforcement interview questions answersTop 9 law enforcement interview questions answers
Top 9 law enforcement interview questions answers
 
Top 9 education interview questions answers
Top 9 education interview questions answersTop 9 education interview questions answers
Top 9 education interview questions answers
 
taj hotel
taj hoteltaj hotel
taj hotel
 
Lindmoor Woods Neighborhood Watch Statistics from 10JULY11 to 31JULY13
Lindmoor Woods Neighborhood Watch Statistics from 10JULY11 to 31JULY13Lindmoor Woods Neighborhood Watch Statistics from 10JULY11 to 31JULY13
Lindmoor Woods Neighborhood Watch Statistics from 10JULY11 to 31JULY13
 
Remarketing seopub
Remarketing seopubRemarketing seopub
Remarketing seopub
 
Top 9 finance interview questions answers
Top 9 finance interview questions answersTop 9 finance interview questions answers
Top 9 finance interview questions answers
 
Top 9 drupal interview questions answers
Top 9 drupal interview questions answersTop 9 drupal interview questions answers
Top 9 drupal interview questions answers
 
Empathy & Define
Empathy & DefineEmpathy & Define
Empathy & Define
 
Top 9 j2ee interview questions answers
Top 9 j2ee interview questions answersTop 9 j2ee interview questions answers
Top 9 j2ee interview questions answers
 
Top 9 jsp servlet interview questions answers
Top 9 jsp servlet interview questions answersTop 9 jsp servlet interview questions answers
Top 9 jsp servlet interview questions answers
 
Cisco Big Data Warehouse Expansion Featuring MapR Distribution
Cisco Big Data Warehouse Expansion Featuring MapR DistributionCisco Big Data Warehouse Expansion Featuring MapR Distribution
Cisco Big Data Warehouse Expansion Featuring MapR Distribution
 
Vision Research Symposium Conference Presentation
Vision Research Symposium Conference PresentationVision Research Symposium Conference Presentation
Vision Research Symposium Conference Presentation
 

Similaire à BioEurope Presentation, March 2010

Act corporate-presentationfeb13
Act corporate-presentationfeb13Act corporate-presentationfeb13
Act corporate-presentationfeb13Company Spotlight
 
Act corporate-presentation jan13
Act corporate-presentation jan13Act corporate-presentation jan13
Act corporate-presentation jan13Company Spotlight
 
World stem cells & regenerative medicine congress, london, may 22, 2013
World stem cells & regenerative medicine congress, london, may 22, 2013World stem cells & regenerative medicine congress, london, may 22, 2013
World stem cells & regenerative medicine congress, london, may 22, 2013Advanced Cell Technology, Inc.
 
2012 World Stem Cell & Regenerative Medicine Congress, London
2012 World Stem Cell & Regenerative Medicine Congress, London2012 World Stem Cell & Regenerative Medicine Congress, London
2012 World Stem Cell & Regenerative Medicine Congress, LondonAdvanced Cell Technology, Inc.
 
Presentation at Bio-Europe Spring 2011 Conference, Milan, Italy. March 2011
Presentation at Bio-Europe Spring 2011 Conference, Milan, Italy. March 2011Presentation at Bio-Europe Spring 2011 Conference, Milan, Italy. March 2011
Presentation at Bio-Europe Spring 2011 Conference, Milan, Italy. March 2011Advanced Cell Technology, Inc.
 
Presentation at OneMedForum, San Francisco. January 2011
Presentation at OneMedForum, San Francisco. January 2011Presentation at OneMedForum, San Francisco. January 2011
Presentation at OneMedForum, San Francisco. January 2011Advanced Cell Technology, Inc.
 
15.15 matthew vincent
15.15 matthew vincent15.15 matthew vincent
15.15 matthew vincentJohn Redaelli
 
Act april13regen-med-investor-day
Act april13regen-med-investor-dayAct april13regen-med-investor-day
Act april13regen-med-investor-dayCompany Spotlight
 
Act annual-shareholders'-meeting-10.22.13
Act annual-shareholders'-meeting-10.22.13Act annual-shareholders'-meeting-10.22.13
Act annual-shareholders'-meeting-10.22.13John Redaelli
 
Roth Capital 24th Annual Growth Stock Conference, Los Angeles
Roth Capital 24th Annual Growth Stock Conference, Los AngelesRoth Capital 24th Annual Growth Stock Conference, Los Angeles
Roth Capital 24th Annual Growth Stock Conference, Los AngelesAdvanced Cell Technology, Inc.
 
Presentation at BIO CEO & Investor Conference, New York City. February 2011
Presentation at BIO CEO & Investor Conference, New York City. February 2011Presentation at BIO CEO & Investor Conference, New York City. February 2011
Presentation at BIO CEO & Investor Conference, New York City. February 2011Advanced Cell Technology, Inc.
 
Presentation at Stem Cells USA & Regenerative medicine Congress 2011 in Bosto...
Presentation at Stem Cells USA & Regenerative medicine Congress 2011 in Bosto...Presentation at Stem Cells USA & Regenerative medicine Congress 2011 in Bosto...
Presentation at Stem Cells USA & Regenerative medicine Congress 2011 in Bosto...Advanced Cell Technology, Inc.
 

Similaire à BioEurope Presentation, March 2010 (20)

Act corporate-presentationfeb13
Act corporate-presentationfeb13Act corporate-presentationfeb13
Act corporate-presentationfeb13
 
Biotech Showcase, San Francisco, Calif., Jan. 8, 2013
Biotech Showcase, San Francisco, Calif., Jan. 8, 2013Biotech Showcase, San Francisco, Calif., Jan. 8, 2013
Biotech Showcase, San Francisco, Calif., Jan. 8, 2013
 
Act corporate-presentation jan13
Act corporate-presentation jan13Act corporate-presentation jan13
Act corporate-presentation jan13
 
Act corp-pres-may13
Act corp-pres-may13Act corp-pres-may13
Act corp-pres-may13
 
World stem cells & regenerative medicine congress, london, may 22, 2013
World stem cells & regenerative medicine congress, london, may 22, 2013World stem cells & regenerative medicine congress, london, may 22, 2013
World stem cells & regenerative medicine congress, london, may 22, 2013
 
2012 World Stem Cell & Regenerative Medicine Congress, London
2012 World Stem Cell & Regenerative Medicine Congress, London2012 World Stem Cell & Regenerative Medicine Congress, London
2012 World Stem Cell & Regenerative Medicine Congress, London
 
Rodman Conference, September 2012
Rodman Conference, September 2012Rodman Conference, September 2012
Rodman Conference, September 2012
 
Presentation at Bio-Europe Spring 2011 Conference, Milan, Italy. March 2011
Presentation at Bio-Europe Spring 2011 Conference, Milan, Italy. March 2011Presentation at Bio-Europe Spring 2011 Conference, Milan, Italy. March 2011
Presentation at Bio-Europe Spring 2011 Conference, Milan, Italy. March 2011
 
Presentation at OneMedForum, San Francisco. January 2011
Presentation at OneMedForum, San Francisco. January 2011Presentation at OneMedForum, San Francisco. January 2011
Presentation at OneMedForum, San Francisco. January 2011
 
15.15 matthew vincent
15.15 matthew vincent15.15 matthew vincent
15.15 matthew vincent
 
Act april13regen-med-investor-day
Act april13regen-med-investor-dayAct april13regen-med-investor-day
Act april13regen-med-investor-day
 
ACT Annual Shareholders' Meeting, October 22, 2013
ACT Annual Shareholders' Meeting, October 22, 2013ACT Annual Shareholders' Meeting, October 22, 2013
ACT Annual Shareholders' Meeting, October 22, 2013
 
Act annual-shareholders'-meeting-10.22.13
Act annual-shareholders'-meeting-10.22.13Act annual-shareholders'-meeting-10.22.13
Act annual-shareholders'-meeting-10.22.13
 
Rodman Conference Presentation: William Caldwell
Rodman Conference Presentation: William CaldwellRodman Conference Presentation: William Caldwell
Rodman Conference Presentation: William Caldwell
 
London Conference Presentation
London Conference PresentationLondon Conference Presentation
London Conference Presentation
 
Roth Capital 24th Annual Growth Stock Conference, Los Angeles
Roth Capital 24th Annual Growth Stock Conference, Los AngelesRoth Capital 24th Annual Growth Stock Conference, Los Angeles
Roth Capital 24th Annual Growth Stock Conference, Los Angeles
 
Presentation at BIO CEO & Investor Conference, New York City. February 2011
Presentation at BIO CEO & Investor Conference, New York City. February 2011Presentation at BIO CEO & Investor Conference, New York City. February 2011
Presentation at BIO CEO & Investor Conference, New York City. February 2011
 
2012 BIO International Convention, Boston
2012 BIO International Convention, Boston2012 BIO International Convention, Boston
2012 BIO International Convention, Boston
 
2014 Biotech Showcase Presentation, January 13, 2014
2014 Biotech Showcase Presentation, January 13, 20142014 Biotech Showcase Presentation, January 13, 2014
2014 Biotech Showcase Presentation, January 13, 2014
 
Presentation at Stem Cells USA & Regenerative medicine Congress 2011 in Bosto...
Presentation at Stem Cells USA & Regenerative medicine Congress 2011 in Bosto...Presentation at Stem Cells USA & Regenerative medicine Congress 2011 in Bosto...
Presentation at Stem Cells USA & Regenerative medicine Congress 2011 in Bosto...
 

Dernier

UiPath Community: AI for UiPath Automation Developers
UiPath Community: AI for UiPath Automation DevelopersUiPath Community: AI for UiPath Automation Developers
UiPath Community: AI for UiPath Automation DevelopersUiPathCommunity
 
UiPath Studio Web workshop series - Day 8
UiPath Studio Web workshop series - Day 8UiPath Studio Web workshop series - Day 8
UiPath Studio Web workshop series - Day 8DianaGray10
 
Babel Compiler - Transforming JavaScript for All Browsers.pptx
Babel Compiler - Transforming JavaScript for All Browsers.pptxBabel Compiler - Transforming JavaScript for All Browsers.pptx
Babel Compiler - Transforming JavaScript for All Browsers.pptxYounusS2
 
Anypoint Code Builder , Google Pub sub connector and MuleSoft RPA
Anypoint Code Builder , Google Pub sub connector and MuleSoft RPAAnypoint Code Builder , Google Pub sub connector and MuleSoft RPA
Anypoint Code Builder , Google Pub sub connector and MuleSoft RPAshyamraj55
 
Salesforce Miami User Group Event - 1st Quarter 2024
Salesforce Miami User Group Event - 1st Quarter 2024Salesforce Miami User Group Event - 1st Quarter 2024
Salesforce Miami User Group Event - 1st Quarter 2024SkyPlanner
 
UiPath Solutions Management Preview - Northern CA Chapter - March 22.pdf
UiPath Solutions Management Preview - Northern CA Chapter - March 22.pdfUiPath Solutions Management Preview - Northern CA Chapter - March 22.pdf
UiPath Solutions Management Preview - Northern CA Chapter - March 22.pdfDianaGray10
 
IaC & GitOps in a Nutshell - a FridayInANuthshell Episode.pdf
IaC & GitOps in a Nutshell - a FridayInANuthshell Episode.pdfIaC & GitOps in a Nutshell - a FridayInANuthshell Episode.pdf
IaC & GitOps in a Nutshell - a FridayInANuthshell Episode.pdfDaniel Santiago Silva Capera
 
Introduction to Quantum Computing
Introduction to Quantum ComputingIntroduction to Quantum Computing
Introduction to Quantum ComputingGDSC PJATK
 
UiPath Platform: The Backend Engine Powering Your Automation - Session 1
UiPath Platform: The Backend Engine Powering Your Automation - Session 1UiPath Platform: The Backend Engine Powering Your Automation - Session 1
UiPath Platform: The Backend Engine Powering Your Automation - Session 1DianaGray10
 
Digital magic. A small project for controlling smart light bulbs.
Digital magic. A small project for controlling smart light bulbs.Digital magic. A small project for controlling smart light bulbs.
Digital magic. A small project for controlling smart light bulbs.francesco barbera
 
GenAI and AI GCC State of AI_Object Automation Inc
GenAI and AI GCC State of AI_Object Automation IncGenAI and AI GCC State of AI_Object Automation Inc
GenAI and AI GCC State of AI_Object Automation IncObject Automation
 
Basic Building Blocks of Internet of Things.
Basic Building Blocks of Internet of Things.Basic Building Blocks of Internet of Things.
Basic Building Blocks of Internet of Things.YounusS2
 
20200723_insight_release_plan_v6.pdf20200723_insight_release_plan_v6.pdf
20200723_insight_release_plan_v6.pdf20200723_insight_release_plan_v6.pdf20200723_insight_release_plan_v6.pdf20200723_insight_release_plan_v6.pdf
20200723_insight_release_plan_v6.pdf20200723_insight_release_plan_v6.pdfJamie (Taka) Wang
 
Using IESVE for Loads, Sizing and Heat Pump Modeling to Achieve Decarbonization
Using IESVE for Loads, Sizing and Heat Pump Modeling to Achieve DecarbonizationUsing IESVE for Loads, Sizing and Heat Pump Modeling to Achieve Decarbonization
Using IESVE for Loads, Sizing and Heat Pump Modeling to Achieve DecarbonizationIES VE
 
COMPUTER 10: Lesson 7 - File Storage and Online Collaboration
COMPUTER 10: Lesson 7 - File Storage and Online CollaborationCOMPUTER 10: Lesson 7 - File Storage and Online Collaboration
COMPUTER 10: Lesson 7 - File Storage and Online Collaborationbruanjhuli
 
How to Effectively Monitor SD-WAN and SASE Environments with ThousandEyes
How to Effectively Monitor SD-WAN and SASE Environments with ThousandEyesHow to Effectively Monitor SD-WAN and SASE Environments with ThousandEyes
How to Effectively Monitor SD-WAN and SASE Environments with ThousandEyesThousandEyes
 
UiPath Studio Web workshop series - Day 6
UiPath Studio Web workshop series - Day 6UiPath Studio Web workshop series - Day 6
UiPath Studio Web workshop series - Day 6DianaGray10
 
Introduction to Matsuo Laboratory (ENG).pptx
Introduction to Matsuo Laboratory (ENG).pptxIntroduction to Matsuo Laboratory (ENG).pptx
Introduction to Matsuo Laboratory (ENG).pptxMatsuo Lab
 
Things you didn't know you can use in your Salesforce
Things you didn't know you can use in your SalesforceThings you didn't know you can use in your Salesforce
Things you didn't know you can use in your SalesforceMartin Humpolec
 
9 Steps For Building Winning Founding Team
9 Steps For Building Winning Founding Team9 Steps For Building Winning Founding Team
9 Steps For Building Winning Founding TeamAdam Moalla
 

Dernier (20)

UiPath Community: AI for UiPath Automation Developers
UiPath Community: AI for UiPath Automation DevelopersUiPath Community: AI for UiPath Automation Developers
UiPath Community: AI for UiPath Automation Developers
 
UiPath Studio Web workshop series - Day 8
UiPath Studio Web workshop series - Day 8UiPath Studio Web workshop series - Day 8
UiPath Studio Web workshop series - Day 8
 
Babel Compiler - Transforming JavaScript for All Browsers.pptx
Babel Compiler - Transforming JavaScript for All Browsers.pptxBabel Compiler - Transforming JavaScript for All Browsers.pptx
Babel Compiler - Transforming JavaScript for All Browsers.pptx
 
Anypoint Code Builder , Google Pub sub connector and MuleSoft RPA
Anypoint Code Builder , Google Pub sub connector and MuleSoft RPAAnypoint Code Builder , Google Pub sub connector and MuleSoft RPA
Anypoint Code Builder , Google Pub sub connector and MuleSoft RPA
 
Salesforce Miami User Group Event - 1st Quarter 2024
Salesforce Miami User Group Event - 1st Quarter 2024Salesforce Miami User Group Event - 1st Quarter 2024
Salesforce Miami User Group Event - 1st Quarter 2024
 
UiPath Solutions Management Preview - Northern CA Chapter - March 22.pdf
UiPath Solutions Management Preview - Northern CA Chapter - March 22.pdfUiPath Solutions Management Preview - Northern CA Chapter - March 22.pdf
UiPath Solutions Management Preview - Northern CA Chapter - March 22.pdf
 
IaC & GitOps in a Nutshell - a FridayInANuthshell Episode.pdf
IaC & GitOps in a Nutshell - a FridayInANuthshell Episode.pdfIaC & GitOps in a Nutshell - a FridayInANuthshell Episode.pdf
IaC & GitOps in a Nutshell - a FridayInANuthshell Episode.pdf
 
Introduction to Quantum Computing
Introduction to Quantum ComputingIntroduction to Quantum Computing
Introduction to Quantum Computing
 
UiPath Platform: The Backend Engine Powering Your Automation - Session 1
UiPath Platform: The Backend Engine Powering Your Automation - Session 1UiPath Platform: The Backend Engine Powering Your Automation - Session 1
UiPath Platform: The Backend Engine Powering Your Automation - Session 1
 
Digital magic. A small project for controlling smart light bulbs.
Digital magic. A small project for controlling smart light bulbs.Digital magic. A small project for controlling smart light bulbs.
Digital magic. A small project for controlling smart light bulbs.
 
GenAI and AI GCC State of AI_Object Automation Inc
GenAI and AI GCC State of AI_Object Automation IncGenAI and AI GCC State of AI_Object Automation Inc
GenAI and AI GCC State of AI_Object Automation Inc
 
Basic Building Blocks of Internet of Things.
Basic Building Blocks of Internet of Things.Basic Building Blocks of Internet of Things.
Basic Building Blocks of Internet of Things.
 
20200723_insight_release_plan_v6.pdf20200723_insight_release_plan_v6.pdf
20200723_insight_release_plan_v6.pdf20200723_insight_release_plan_v6.pdf20200723_insight_release_plan_v6.pdf20200723_insight_release_plan_v6.pdf
20200723_insight_release_plan_v6.pdf20200723_insight_release_plan_v6.pdf
 
Using IESVE for Loads, Sizing and Heat Pump Modeling to Achieve Decarbonization
Using IESVE for Loads, Sizing and Heat Pump Modeling to Achieve DecarbonizationUsing IESVE for Loads, Sizing and Heat Pump Modeling to Achieve Decarbonization
Using IESVE for Loads, Sizing and Heat Pump Modeling to Achieve Decarbonization
 
COMPUTER 10: Lesson 7 - File Storage and Online Collaboration
COMPUTER 10: Lesson 7 - File Storage and Online CollaborationCOMPUTER 10: Lesson 7 - File Storage and Online Collaboration
COMPUTER 10: Lesson 7 - File Storage and Online Collaboration
 
How to Effectively Monitor SD-WAN and SASE Environments with ThousandEyes
How to Effectively Monitor SD-WAN and SASE Environments with ThousandEyesHow to Effectively Monitor SD-WAN and SASE Environments with ThousandEyes
How to Effectively Monitor SD-WAN and SASE Environments with ThousandEyes
 
UiPath Studio Web workshop series - Day 6
UiPath Studio Web workshop series - Day 6UiPath Studio Web workshop series - Day 6
UiPath Studio Web workshop series - Day 6
 
Introduction to Matsuo Laboratory (ENG).pptx
Introduction to Matsuo Laboratory (ENG).pptxIntroduction to Matsuo Laboratory (ENG).pptx
Introduction to Matsuo Laboratory (ENG).pptx
 
Things you didn't know you can use in your Salesforce
Things you didn't know you can use in your SalesforceThings you didn't know you can use in your Salesforce
Things you didn't know you can use in your Salesforce
 
9 Steps For Building Winning Founding Team
9 Steps For Building Winning Founding Team9 Steps For Building Winning Founding Team
9 Steps For Building Winning Founding Team
 

BioEurope Presentation, March 2010

  • 1. Advanced Cell Technology Corporate Presentation March 2010 1
  • 2. This presentation is intended to present a summary of ACT’s (“ACT”, or “Advanced Cell Technology Inc”, or “the Company”) salient business characteristics. The information herein contains “forward-looking statements” as defined under the federal securities laws. Actual results could vary materially. Factors that could cause actual results to vary materially are described in our filings with the Securities and Exchange Commission. You should pay particular attention to the “risk factors” contained in documents we file from time to time with the Securities and Exchange Commission. The risks identified therein, as well as others not identified by the Company, could cause the Company’s actual results to differ materially from those expressed in any forward- looking statements. Cautionary Statement Concerning Forward-Looking Statements 2
  • 3. ACT Therapeutics ACT Proprietary Human Therapeutic Programs Treatment Clinical Stage Blastomere Program Development of embryonic stem cell lines without destruction of embryo Pre-Clinical Retinal Pigment Epithelium (RPE) Program Treatment of Age-related Macular Degeneration (AMD) and Retinal Degenerative Diseases Clinical IND awaiting FDA approval Myoblast Program Treatment of Heart Disease, Heart Attack and Heart Failure Phase II Hemangioblast program Treatment of Diseases and Disorders of the Circulatory and Vascular Systems Pre-Clinical 3
  • 4. Pending Multiple next generation technologies complementary to existing patents and claims PendingMultiple use patents for heart disease StatusUse Patents PendingCombinations of myoblasts and stem cells PendingCombinations of myoblasts and muscle survival factors PendingCatheter delivery of cells AwardedMedia for preservation and transplant of muscle cells AwardedStem cells capable of forming nerve or muscle cells AwardedMuscle cells StatusComposition of Matter Patent Intellectual Property Protection ACT owns or licenses over 150 patents and patent applications related to stem cell and regenerative therapies 4
  • 5. Institutional Collaborators Advanced Cell’s Institutional Collaborators include: Casey Eye Institute Mayo Clinic Moran Eye Institute UCSF Harvard Johns Hopkins Stanford Sloan Kettering University of Florida University of Iowa University of Illinois U.C. Berkeley Colorado State University 5
  • 6. Blastomere Program: Synthesizing Stem Cells without Harm to the Embryo •Company scientists successfully generate stem cell lines without destruction of embryo •Cell lines retain potential to form all cells in the human body •Potential to treat a range of human diseases •Technology has been reproduced and peer- reviewed on several occasions •National Institute of Health (NIH) proposing expanded funding regulations to accommodate ACT’s lines 6
  • 7. First Proven Alternative hESC Method •Enables Derivation of New hESC Lines via Pre-implantation Genetic Diagnosis (PGD) Method, Preserving Development Potential of the Embryo •7 hESC lines awaiting NIH approval for funding •Technology is used to develop RPE cells for our clinical trials for Stargardt’s disease Hemangioblasts Differentiated from Blastomere hESC Lines 7
  • 8. RPE Program: Why RPE? • Pigmented epithelium cells are easy to identify • Small dosage vs. other therapies • The eye is an immune-privileged site, thus no risk of rejection at the injection site • Ease of administration – Doesn’t require a separate approval by the FDA (universal applicator) – Procedure is already used by eye surgeons; no new skill set required for doctors • RPE cell therapy may positively impact over 200 retinal diseases 8
  • 9. RPE Program Status Complete Stage 1 of Phase I Clinical Trial for Stargardt’s disease2010 – 4th Quarter Developed the “Proof of Concept” for ACT’s RPE cells in RCS animal model2006 Pre – IND meeting with FDA2008 Filed IND for Stargardt’s disease2009 FDA approval2010 – 3rd Quarter 9
  • 10. GMP-compliant Human RPE Cells Derived from Embryonic Stem Cell Lines Rescue Visual Function In a Rat Model for Photoreceptor Degeneration “Our results show that a well-characterized GMP-compliant embryonic stem cell-derived RPE cells can survive after transplantation to the sub-retinal space of RCS rats, integrate into host RPE layer without migration into the retina and continue to express at least some of the molecules characteristic of RPE. The cells are effective in rescuing photoreceptors from degeneration and result in significant rescue of visual function over sham-operated animals for the long term.” CASEY EYE INSTITUTE 10
  • 11. Myoblast Program Highlights Target Market for Myoblast Program Sufferers of Heart Failure, Chronic Heart Failure and patients with scarred or ischemic (dead) heart tissue caused by or related to heart attack Program Status Clearance from FDA to Proceed with Phase II Clinical Trials in the U.S. Charlestown, MA GMP Facility 11
  • 12. Myoblast Program: Clinical Trial Summary Phase 1 LVAD Phase 1 CABG Phase 1b CABG Phase 1b Catheter Patients 6 patients 12 patients 12 patients 23 Patients (12 treated, 11 control) Indication LVAD Bridge to Transplant +CABG +CABG Catheter Injection Dose Single Dose - 300 MM Cells Escalating – 10, 30, 100 and 300 MM Cells Single Dose - 300 MM Cells Escalating - 30, 100, 300 and 600 MM Cells Primary Endpoint Safety Safety Safety Safety Result Demonstrated cell survival in humans Dose escalation, Safe at all doses Survival of cells (cardiac imaging), improved symptoms and function Safe at all doses, improved symptoms and function 12
  • 13. Myoblast Program: Phase II Clinical Trial  80 total patients (1:1 treatment vs. control)  Double-blind, placebo-controlled (sham procedure)  Catheter delivery of cells: percutaneous targeted delivery  Three-month, six-month, and 12-month follow-up  Endpoints: Improvement in HF symptoms and Ventricular Volumes  Primary endpoint: Improvement in heart failure symptoms measured by “Kansas City Cardiomyopathy Questionnaire”  Supporting endpoints: Ventricular volumes, Six minute walk test  Interim data analysis at six-months by Independent Review Board 13
  • 14. Hemangioblast Program: Partnership • Joint Venture with leading Korean stem cell developer CHA Biotech Co. • The J.V., ‘Stem Cell & Regenerative Medicine International’, is focused on the development of human blood cells and related products 14
  • 15. Hemangioblast Program: Overview The HG cell is the precursor to all cell types in the circulatory and vascular systems 15
  • 17. The ACT Therapeutic Timeline Timetable for Therapeutic Program Milestones Period Received Orphan indication from Department of Health and Human Services Q1 2010 Completion of end of life tumorgenicity & biodistribution Q1 2010 Receive FDA clearance to commence with Phase I Clinical Trials Q3 2010 Treat 1st Patient in history with a hECS-based therapy Q3 2010 1st Quadrant Safety Data on Treated Patients Q4 2010 File 2nd Phase I IND for another Retinal Disease 2nd half 2010 Announce 2nd cellular-based IND in area other than retinal program 2nd half 2010 studies for RPE 17
  • 18. The Advanced Cell Technology Team World Class Scientific Team lead by Seasoned Management Team: Dr. Robert Lanza, M.D. – Chief Scientific Officer Dr. Jonathan Dinsmore, PhD – Myoblast Project Advisor Edmund Mickunas – Vice President of Regulatory William Caldwell IV – Chief Executive Officer Rita Parker – Director of Operations Roger Gay, PhD – Senior Director of Manufacturing Matthew Vincent, PhD – IP / Licensing Advisor 18
  • 19. State of the Company • Two years of cash available • Phase I/II trial fully funded • Anticipating cell lines will qualify for federal funding • Actively pursuing development partners offshore to accelerate development of programs 19
  • 20. Thank you for your time For more information, visit www.advancedcell.com Advanced Cell Technology is traded on the OTC BB, symbol: ACTC